- Avant Technologies (OTCQB: AVAI) and Ainnova Tech are in discussions to license or acquire innovative early disease detection technology.
- The potential deal would enhance preventive health reporting without complete patient data and integrate into their Vision AI platform.
- The companies have already integrated four algorithms and view retinal exams as a vital sign for comprehensive health reporting.
Avant Technologies, Inc. (OTCQB: AVAI) and its joint venture partner Ainnova Tech are currently in talks with an international healthcare innovation company to license or potentially acquire its patented technology for early disease detection. The collaboration aims to advance preventive health reporting capabilities by allowing disease detection correlation without the necessity of having complete patient data.
Building on their AI-driven Vision AI technology platform, Avant and Ainnova strive to make early disease detection more accessible and cost-effective. The firms have successfully integrated four algorithms into the Vision AI platform through exclusive licensing, highlighting the potential of combining retinal examination with laboratory tests and basic patient data to produce comprehensive health reports.
Vinicio Vargas, Ainnova's CEO and a board member of Ai-nova Acquisition Corp., expressed the mission to facilitate preventive check-ups affordably and easily, aiming to prevent diseases early, especially for patients with risk factors. Vargas emphasized the strategic intent of Avant and Ainnova to continue integrating new technologies into their portfolio, enhancing the spectrum of preventive healthcare solutions.
While the discussions are in their initial phase, a successful deal could revolutionize the way preventive health reporting is conducted globally. Avant Technologies has committed to updating its shareholders as the talks progress.
